Maintenance therapy following allogeneic hematopoietic stem cell transplantation in myeloid neoplasms
10.3760/cma.j.cn115356-20220207-00032
- VernacularTitle:髓系恶性肿瘤异基因造血干细胞移植后的维持治疗
- Author:
Xinhui ZHENG
1
;
Erlie JIANG
Author Information
1. 中国医学科学院血液病医院（中国医学科学院血液学研究所） 实验血液学国家重点实验室 国家血液系统疾病临床医学研究中心 细胞生态海河实验室，天津 300020
- Keywords:
Leukemia, myeloid, acute;
Myelodysplastic syndromes;
Allogeneic hematopoietic stem cell transplantation;
Maintenance therapy
- From:
Journal of Leukemia & Lymphoma
2023;32(8):505-509
- CountryChina
- Language:Chinese
-
Abstract:
The acute myeloid leukemia and myelodysplastic syndromes are common myeloid neoplasms for which allogeneic hematopoietic stem cell transplantation is one of the main curative therapies. In high-risk patients, the relapse rate can be more than 40%, and patients with post-transplantation relapses have a very poor prognosis, so preventing relapse after transplantation is crucial. The maintenance therapy is a group of interventions to prevent relapse when morphological, molecular biological and cytogenetic results are constantly negative after transplantation. Currently, the commonly used maintenance therapy is the application of demethylating drugs, targeted drugs, etc., but their necessity, medicine plan, adverse effects, multi-drug combinations, and other aspects need to be studied urgently. This article will systematically describe the progress of post-transplantation maintenance therapy for high-risk myeloid neoplasms based on drug classification.
